MEK inhibitors for the treatment of non-small cell lung cancer
BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK...
Uložené v:
| Vydané v: | Journal of hematology and oncology Ročník 14; číslo 1; s. 1 - 12 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
05.01.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1756-8722, 1756-8722 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer. |
|---|---|
| AbstractList | BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer. BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer.BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer. Abstract BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer. BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer. Keywords: Non-small cell lung cancer, MEK inhibitors, Targeted therapy, RAS, RAF, MEK, ERK signaling pathway |
| ArticleNumber | 1 |
| Audience | Academic |
| Author | Wang, Qiming Liu, Yang Han, Jing Li, Hongle Wu, Xuan Yang, Sen |
| Author_xml | – sequence: 1 givenname: Jing surname: Han fullname: Han, Jing organization: Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital – sequence: 2 givenname: Yang surname: Liu fullname: Liu, Yang organization: Department of Radiotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital – sequence: 3 givenname: Sen surname: Yang fullname: Yang, Sen organization: Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital – sequence: 4 givenname: Xuan surname: Wu fullname: Wu, Xuan organization: Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital – sequence: 5 givenname: Hongle surname: Li fullname: Li, Hongle email: llhl73@163.com organization: Department of Molecular Pathology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital – sequence: 6 givenname: Qiming orcidid: 0000-0003-3217-1077 surname: Wang fullname: Wang, Qiming email: qimingwang1006@126.com organization: Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33402199$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt1r1TAYxotM3If-A15IQRBvOvPRJM3NYIypw4k3eh3SnDc9ObTJTNKB_73pzubOGTIKbXj7PL80T5_j6sAHD1X1FqNTjDv-KWGKWtYgghqEEWGNeFEdYcF40wlCDnbWh9VxShuEOJYEvaoOKW0RwVIeVWffL7_Vzq9d73KIqbYh1nkNdY6g8wQ-18HWZd8mTXocawPlNs5-qI32BuLr6qXVY4I398-T6tfny58XX5vrH1-uLs6vGyNQmxvTAtZ4ZRBjIKUGzLXg3FordI91LzUTnSEcAwHELeMttxqAkx6RnmC6oifV1Za7CnqjbqKbdPyjgnbqbhDioHTMzoygOm0pMcZQamlLcaspo4zLMpSMdy0vrLMt62buJ1iZcsioxz3o_hvv1moIt0qIjjMsC-DjPSCG3zOkrCaXlmS0hzAnRVrBWPk1Ahfp-yfSTZijL1Etqk4wKRF7VA26HMB5G8q-ZoGqc84Q6zrCRFGd_kdVrhVMzpRqWFfme4YPO4Y16DGvUxjn7IJP-8J3u4n8i-KhJkXQbQUmhpQiWGVc1gunfIIbFUZqaaTaNlKVRqq7RqqFTZ5YH-jPmujWlIrYDxAfY3vG9ReEZu6r |
| CitedBy_id | crossref_primary_10_1016_j_jep_2023_116565 crossref_primary_10_1002_anbr_202400084 crossref_primary_10_1016_j_molliq_2022_118562 crossref_primary_10_1007_s13402_023_00867_w crossref_primary_10_3389_fonc_2022_903177 crossref_primary_10_1186_s41927_021_00237_9 crossref_primary_10_3389_fimmu_2023_1233085 crossref_primary_10_3390_cancers17050853 crossref_primary_10_1016_j_clinsp_2024_100406 crossref_primary_10_1016_j_biopha_2023_115079 crossref_primary_10_1038_s41467_022_29292_7 crossref_primary_10_1016_j_tranon_2024_101978 crossref_primary_10_3389_fonc_2023_1293441 crossref_primary_10_1016_j_heliyon_2024_e24236 crossref_primary_10_1016_j_ijbiomac_2024_138621 crossref_primary_10_1039_D5BM01193K crossref_primary_10_1051_bioconf_202518202001 crossref_primary_10_1016_j_currproblcancer_2024_101106 crossref_primary_10_3389_fphar_2023_1132158 crossref_primary_10_1038_s41419_023_05592_8 crossref_primary_10_1016_j_advms_2023_02_004 crossref_primary_10_1016_j_jddst_2022_103865 crossref_primary_10_1002_cbdv_202301422 crossref_primary_10_1007_s12032_022_01744_6 crossref_primary_10_1016_j_jbc_2025_110647 crossref_primary_10_1038_s41419_024_07082_x crossref_primary_10_1111_aji_13689 crossref_primary_10_1155_2022_3351268 crossref_primary_10_3390_pharmaceutics14010059 crossref_primary_10_1016_j_jbc_2025_108164 crossref_primary_10_1186_s13765_024_00952_0 crossref_primary_10_1158_0008_5472_CAN_22_1039 crossref_primary_10_1002_adhm_202403019 crossref_primary_10_1016_j_critrevonc_2021_103454 crossref_primary_10_3390_cancers15184581 crossref_primary_10_1242_bio_060448 crossref_primary_10_1186_s12885_021_09097_5 crossref_primary_10_3390_cancers16122189 crossref_primary_10_1038_s41597_023_02543_y crossref_primary_10_1186_s40959_023_00197_8 crossref_primary_10_1002_advs_202415772 crossref_primary_10_3390_ijms25136961 crossref_primary_10_1186_s12944_021_01599_2 crossref_primary_10_1007_s11033_023_08832_4 crossref_primary_10_1097_COC_0000000000001049 crossref_primary_10_1088_1555_6611_acd7dc crossref_primary_10_1371_journal_pcbi_1011095 crossref_primary_10_1186_s40164_022_00361_3 crossref_primary_10_1016_j_canlet_2023_216426 crossref_primary_10_1111_jgh_15937 crossref_primary_10_3389_fmars_2022_1057814 crossref_primary_10_1172_JCI161308 crossref_primary_10_1186_s12885_025_14033_y crossref_primary_10_1073_pnas_2201423119 crossref_primary_10_1007_s11033_023_09174_x crossref_primary_10_1186_s10020_024_00934_4 crossref_primary_10_1186_s13287_021_02659_1 crossref_primary_10_3389_fgene_2023_1106665 crossref_primary_10_1038_s41568_024_00679_6 crossref_primary_10_3390_molecules27051590 crossref_primary_10_3389_fimmu_2023_1132601 crossref_primary_10_1007_s12032_023_02071_0 crossref_primary_10_3389_fphar_2022_841687 crossref_primary_10_3390_cancers14194863 crossref_primary_10_1186_s40364_021_00281_0 crossref_primary_10_1186_s13287_023_03473_7 crossref_primary_10_1007_s11033_023_08929_w crossref_primary_10_3390_cancers13236005 crossref_primary_10_1002_iju5_12672 crossref_primary_10_1186_s12890_024_03178_4 crossref_primary_10_1186_s12916_023_03182_1 crossref_primary_10_3389_fonc_2024_1376502 crossref_primary_10_3389_fonc_2021_741326 crossref_primary_10_1002_mco2_715 crossref_primary_10_3390_molecules28155746 crossref_primary_10_1038_s41598_023_44372_4 crossref_primary_10_3390_molecules28020692 crossref_primary_10_3892_ol_2024_14320 crossref_primary_10_1016_j_tice_2022_101941 crossref_primary_10_1080_07391102_2022_2158137 crossref_primary_10_1002_ange_202507586 crossref_primary_10_3389_fimmu_2025_1620225 crossref_primary_10_3389_fsysb_2023_1112831 crossref_primary_10_3390_cancers15082375 crossref_primary_10_1002_chem_202402485 crossref_primary_10_1007_s11051_024_06008_0 crossref_primary_10_1007_s12325_022_02163_9 crossref_primary_10_1002_adtp_202500006 crossref_primary_10_3390_cancers14194769 crossref_primary_10_1016_j_intimp_2022_109031 crossref_primary_10_3390_cells11182871 crossref_primary_10_1016_j_ccr_2023_215624 crossref_primary_10_3390_cancers13235905 crossref_primary_10_1016_j_bios_2024_116565 crossref_primary_10_1242_dmm_049627 crossref_primary_10_3389_fonc_2022_910505 crossref_primary_10_1002_adbi_202400140 crossref_primary_10_1016_j_bbcan_2024_189108 crossref_primary_10_1186_s40164_024_00528_0 crossref_primary_10_1111_1759_7714_14388 crossref_primary_10_1007_s12032_024_02547_7 crossref_primary_10_1007_s00284_022_02807_7 crossref_primary_10_3390_ijms241411851 crossref_primary_10_1002_advs_202402954 crossref_primary_10_3389_fonc_2022_1045521 crossref_primary_10_1177_15330338231202391 crossref_primary_10_1186_s12920_023_01543_6 crossref_primary_10_3390_cancers15123088 crossref_primary_10_1002_adfm_202416813 crossref_primary_10_1016_j_bbrc_2025_152204 crossref_primary_10_1016_j_bcp_2024_116572 crossref_primary_10_1158_1535_7163_MCT_24_0593 crossref_primary_10_1016_j_cellsig_2023_110962 crossref_primary_10_3389_fonc_2023_1285593 crossref_primary_10_1007_s10528_025_11148_6 crossref_primary_10_1016_j_jval_2022_11_018 crossref_primary_10_1039_D2BM01181F crossref_primary_10_1007_s40487_022_00184_6 crossref_primary_10_1016_j_heliyon_2023_e22515 crossref_primary_10_1016_j_mgene_2020_100799 crossref_primary_10_1186_s13040_025_00444_x crossref_primary_10_1038_s41467_023_40235_8 crossref_primary_10_3892_ijmm_2023_5271 crossref_primary_10_1016_j_mtbio_2025_102070 crossref_primary_10_1177_17588359241308784 crossref_primary_10_1142_S1088424622500328 crossref_primary_10_1038_s41416_022_02093_x crossref_primary_10_1186_s40001_023_01449_0 crossref_primary_10_1142_S1793984424300127 crossref_primary_10_1016_S1875_5364_23_60521_7 crossref_primary_10_1038_s41598_024_71317_2 crossref_primary_10_1007_s12013_024_01492_6 crossref_primary_10_3390_biomedicines10040921 crossref_primary_10_3390_pharmaceutics16080981 crossref_primary_10_1002_mco2_401 crossref_primary_10_1007_s00894_023_05520_9 crossref_primary_10_3389_fgene_2022_985077 crossref_primary_10_1016_j_lungcan_2021_06_002 crossref_primary_10_1038_s41392_025_02382_w crossref_primary_10_1016_j_jaccao_2022_01_096 crossref_primary_10_1186_s40246_023_00528_x crossref_primary_10_3390_ijms25094633 crossref_primary_10_1007_s13369_025_10157_2 crossref_primary_10_1007_s10495_022_01789_y crossref_primary_10_1016_j_omto_2022_04_006 crossref_primary_10_1093_bib_bbab187 crossref_primary_10_1016_j_bbadis_2022_166353 crossref_primary_10_3389_fonc_2023_1216131 crossref_primary_10_1007_s00204_023_03600_6 crossref_primary_10_1016_j_lungcan_2024_107964 crossref_primary_10_1186_s12943_024_02069_w crossref_primary_10_1007_s00210_023_02447_z crossref_primary_10_1007_s00432_022_04158_z crossref_primary_10_1007_s10989_023_10542_1 crossref_primary_10_1016_j_biopha_2022_113959 crossref_primary_10_1038_s41419_025_07711_z crossref_primary_10_3390_cancers15051578 crossref_primary_10_1007_s13318_023_00826_8 crossref_primary_10_1016_j_bmc_2023_117336 crossref_primary_10_1016_j_abb_2023_109637 crossref_primary_10_1158_0008_5472_CAN_25_1464 |
| Cites_doi | 10.1056/NEJMoa1408868 10.3390/molecules22101551 10.3322/caac.21387 10.2174/157436209788167466 10.1016/j.lungcan.2019.04.027 10.3390/cancers12102870 10.1016/j.molcel.2005.04.001 10.1038/bjc.2015.215 10.1001/jama.2017.3438 10.1001/jama.2017.3436 10.3892/ol.2015.3577 10.1016/j.canlet.2015.04.028 10.1016/S1470-2045(17)30679-4 10.1016/S1470-2045(12)70489-8 10.1093/annonc/mdx628 10.1093/jjco/hyx144 10.1016/j.cellsig.2015.07.003 10.1016/j.cllc.2020.02.019 10.1186/s40425-017-0268-8 10.1073/pnas.0905833106 10.1038/nature12441 10.1186/1756-9966-33-52 10.1016/j.bbamcr.2006.10.005 10.1056/NEJMoa1412690 10.1371/journal.pone.0014124 10.1111/cas.13763 10.1158/0008-5472.CAN-11-1515 10.1016/S0140-6736(16)32517-X 10.1016/j.celrep.2019.03.066 10.1007/s10637-019-00776-6 10.1158/0008-5472.CAN-09-0679 10.1007/s11523-020-00714-0 10.1200/JCO.20.00762 10.1124/dmd.115.067181 10.1097/JTO.0b013e3181e8b3a3 10.1038/nm.1890 10.1021/bi801898e 10.1021/ml300049d 10.3322/caac.21492 10.1593/neo.09398 10.1093/annonc/mdv072 10.1634/theoncologist.2019-0297 10.1200/JCO.2014.58.2007 10.1038/nrc969 10.1016/S0025-6196(11)60735-0 10.1093/annonc/mdw008 10.1158/1078-0432.CCR-09-1920 10.1200/JCO.2011.35.9638 10.1093/emboj/16.8.1901 10.1158/1538-7445.AM10-2515 10.1158/1078-0432.CCR-06-1150 10.1038/bjc.2017.271 10.1016/j.jtho.2016.11.2218 10.1007/s10637-020-00975-6 10.1007/s00280-020-04038-8 10.1158/1078-0432.CCR-12-0742 10.1016/j.ctrv.2016.12.001 10.1158/1078-0432.CCR-10-2200 10.1016/S0140-6736(15)01281-7 10.2478/v10039-011-0043-x 10.1093/annonc/mdz113 10.1016/S1470-2045(16)30146-2 10.1016/S1470-2045(16)00077-2 10.1038/35065000 10.1016/j.ygyno.2015.05.031 10.1016/j.celrep.2013.08.023 10.1586/17476348.2016.1115349 10.1016/j.annonc.2020.01.013 10.1007/s40265-018-0884-8 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13045-020-01025-7 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-8722 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_8af32ccc33f34314a353569f32956846 PMC7786519 A650588257 33402199 10_1186_s13045_020_01025_7 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Foundation for Distinguished Young Talents in Higher Education of Henan (CN) grantid: No. 201082; No. 18HASTIT044 – fundername: Provincial Secretariat for Science and Technological Development (RS) grantid: No. 2011020155 – fundername: Henan Provincial Research Program of Application Foundation and Advanced Technology grantid: No. 112300410033 – fundername: Jiangsu Agricultural Science and Technology Independent Innovation Fund (CN) grantid: No. [2016]32 – fundername: the National Natural Science Foundation of China grantid: No. 81272600 – fundername: Wu Yingkai Foundation for Medical Research and Development (CN) grantid: No. 320.6799.15018 – fundername: Medical Science and Technology Foundation of Henan Province grantid: No. 201601026 – fundername: Science and Technology Department of Henan Province (CN) grantid: No. 201601026 – fundername: ; grantid: No. 112300410033 – fundername: ; grantid: No. 320.6799.15018 – fundername: ; grantid: No. 81272600 – fundername: ; grantid: No. 2011020155 – fundername: ; grantid: No. 201082; No. 18HASTIT044 – fundername: ; grantid: No. 201601026 – fundername: ; grantid: No. [2016]32 |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP ~8M AAYXX AFFHD CITATION ALIPV NPM 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c704t-c4e1a1dc055e99ae16a766fff7ab1ab9a578c261e2e06f5646faee62b02b213d3 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 138 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000607951800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1756-8722 |
| IngestDate | Mon Nov 10 04:32:27 EST 2025 Tue Nov 04 02:00:45 EST 2025 Sun Nov 09 09:23:39 EST 2025 Sun Oct 19 00:05:31 EDT 2025 Tue Nov 11 07:39:46 EST 2025 Tue Nov 04 17:46:17 EST 2025 Thu May 22 21:06:15 EDT 2025 Thu Apr 03 07:06:47 EDT 2025 Sat Nov 29 06:33:49 EST 2025 Tue Nov 18 21:32:21 EST 2025 Sat Sep 06 07:24:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | MEK Targeted therapy RAS MEK inhibitors RAF ERK signaling pathway Non-small cell lung cancer |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c704t-c4e1a1dc055e99ae16a766fff7ab1ab9a578c261e2e06f5646faee62b02b213d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-3217-1077 |
| OpenAccessLink | https://www.proquest.com/docview/2478759905?pq-origsite=%requestingapplication% |
| PMID | 33402199 |
| PQID | 2478759905 |
| PQPubID | 54946 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_8af32ccc33f34314a353569f32956846 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7786519 proquest_miscellaneous_2475530471 proquest_journals_2478759905 gale_infotracmisc_A650588257 gale_infotracacademiconefile_A650588257 gale_healthsolutions_A650588257 pubmed_primary_33402199 crossref_citationtrail_10_1186_s13045_020_01025_7 crossref_primary_10_1186_s13045_020_01025_7 springer_journals_10_1186_s13045_020_01025_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-05 |
| PublicationDateYYYYMMDD | 2021-01-05 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of hematology and oncology |
| PublicationTitleAbbrev | J Hematol Oncol |
| PublicationTitleAlternate | J Hematol Oncol |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | YJ Guo (1025_CR15) 2020; 19 SK Hong (1025_CR18) 2015; 27 AKS Salama (1025_CR42) 2020; 38 E Poon (1025_CR55) 2017; 5 RS Herbst (1025_CR53) 2016; 387 M Fukuda (1025_CR13) 1997; 16 AG Gilmartin (1025_CR24) 2011; 17 JD Hainsworth (1025_CR36) 2010; 5 L Chang (1025_CR16) 2001; 410 GR Oxnard (1025_CR60) 2020; 31 AW Tolcher (1025_CR73) 2020; 85 E Martinelli (1025_CR8) 2017; 53 KD Rice (1025_CR29) 2012; 3 JN Sanchez (1025_CR9) 2018; 78 J Villanueva (1025_CR63) 2013; 4 RK Ramanathan (1025_CR77) 2020; 15 A Marchetti (1025_CR5) 2011; 29 TC Yeh (1025_CR23) 2007; 13 G Hatzivassiliou (1025_CR33) 2013; 501 D Planchard (1025_CR40) 2016; 17 1025_CR74 I Falcone (1025_CR70) 2020; 12 RH Takahashi (1025_CR34) 2015; 43 M Takekawa (1025_CR14) 2005; 18 PA Jänne (1025_CR47) 2017; 317 JR Molina (1025_CR3) 2008; 83 1025_CR4 TO Fischmann (1025_CR11) 2009; 48 Y Qu (1025_CR71) 2014; 33 D Planchard (1025_CR41) 2017; 18 F Bray (1025_CR1) 2018; 68 T Seto (1025_CR51) 2018; 48 A Rittmeyer (1025_CR52) 2017; 389 GI Shapiro (1025_CR76) 2020; 38 Y Cheng (1025_CR27) 2017; 22 J Kaufman (1025_CR48) 2017; 317 W Yao (1025_CR66) 2015; 364 J Larkin (1025_CR6) 2014; 371 H Li (1025_CR69) 2011; 56 A Greystoke (1025_CR50) 2017; 117 MD Hellmann (1025_CR56) 2019; 30 1025_CR19 EB Haura (1025_CR37) 2010; 16 M Martinez-Garcia (1025_CR35) 2012; 18 B Melosky (1025_CR44) 2019; 133 C Robert (1025_CR7) 2015; 372 B Ricciuti (1025_CR10) 2016; 10 CM Emery (1025_CR64) 2009; 106 GR Blumenschein Jr (1025_CR38) 2015; 26 DR Gandara (1025_CR46) 2017; 12 L Ciuffreda (1025_CR65) 2009; 4 JC Soria (1025_CR49) 2017; 28 S Li (1025_CR58) 2015; 10 RL Siegel (1025_CR2) 2017; 67 A Lopez-Chavez (1025_CR39) 2015; 33 YD Shaul (1025_CR12) 2007; 1773 KP Hoeflich (1025_CR26) 2012; 72 C Iverson (1025_CR32) 2009; 69 D Planchard (1025_CR72) 2016; 17 H Choi (1025_CR54) 2019; 27 1025_CR28 J Meng (1025_CR67) 2010; 5 L Ciuffreda (1025_CR31) 2009; 11 PA Jänne (1025_CR45) 2015; 113 JA Engelman (1025_CR68) 2008; 14 PA Jänne (1025_CR43) 2013; 14 1025_CR61 A Bardia (1025_CR75) 2020; 25 CA Carter (1025_CR59) 2016; 27 1025_CR22 J Downward (1025_CR17) 2003; 3 K Inaba (1025_CR30) 2015; 138 1025_CR25 PO Gaudreau (1025_CR57) 2020; 21 1025_CR62 H Sato (1025_CR78) 2018; 109 1025_CR20 1025_CR21 |
| References_xml | – volume: 371 start-page: 1867 issue: 20 year: 2014 ident: 1025_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa1408868 – volume: 22 start-page: 1551 issue: 10 year: 2017 ident: 1025_CR27 publication-title: Molecules doi: 10.3390/molecules22101551 – volume: 67 start-page: 7 issue: 1 year: 2017 ident: 1025_CR2 publication-title: CA Cancer J Clin doi: 10.3322/caac.21387 – volume: 4 start-page: 130 issue: 2 year: 2009 ident: 1025_CR65 publication-title: Curr. Signal Transduct Ther. doi: 10.2174/157436209788167466 – volume: 133 start-page: 48 year: 2019 ident: 1025_CR44 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2019.04.027 – volume: 12 start-page: 2870 issue: 10 year: 2020 ident: 1025_CR70 publication-title: Cancers (Basel) doi: 10.3390/cancers12102870 – ident: 1025_CR22 – volume: 18 start-page: 295 issue: 3 year: 2005 ident: 1025_CR14 publication-title: Mol Cell doi: 10.1016/j.molcel.2005.04.001 – volume: 113 start-page: 199 issue: 2 year: 2015 ident: 1025_CR45 publication-title: Br J Cancer doi: 10.1038/bjc.2015.215 – volume: 317 start-page: 1844 issue: 18 year: 2017 ident: 1025_CR47 publication-title: JAMA doi: 10.1001/jama.2017.3438 – volume: 317 start-page: 1835 issue: 18 year: 2017 ident: 1025_CR48 publication-title: JAMA doi: 10.1001/jama.2017.3436 – volume: 10 start-page: 2652 issue: 4 year: 2015 ident: 1025_CR58 publication-title: Oncol Lett doi: 10.3892/ol.2015.3577 – ident: 1025_CR61 – ident: 1025_CR4 – volume: 364 start-page: 70 issue: 1 year: 2015 ident: 1025_CR66 publication-title: Cancer Lett doi: 10.1016/j.canlet.2015.04.028 – volume: 18 start-page: 1307 issue: 10 year: 2017 ident: 1025_CR41 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30679-4 – volume: 14 start-page: 38 issue: 1 year: 2013 ident: 1025_CR43 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70489-8 – volume: 28 start-page: 3028 issue: 12 year: 2017 ident: 1025_CR49 publication-title: Ann Oncol doi: 10.1093/annonc/mdx628 – volume: 48 start-page: 31 issue: 1 year: 2018 ident: 1025_CR51 publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyx144 – volume: 27 start-page: 1939 issue: 10 year: 2015 ident: 1025_CR18 publication-title: Cell Signal doi: 10.1016/j.cellsig.2015.07.003 – ident: 1025_CR21 – volume: 21 start-page: 384 issue: 4 year: 2020 ident: 1025_CR57 publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2020.02.019 – volume: 5 start-page: 63 issue: 1 year: 2017 ident: 1025_CR55 publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0268-8 – volume: 106 start-page: 20411 issue: 48 year: 2009 ident: 1025_CR64 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0905833106 – volume: 501 start-page: 232 issue: 7466 year: 2013 ident: 1025_CR33 publication-title: Nature doi: 10.1038/nature12441 – volume: 33 start-page: 52 year: 2014 ident: 1025_CR71 publication-title: J Exp Clin Cancer Res doi: 10.1186/1756-9966-33-52 – ident: 1025_CR20 – ident: 1025_CR62 – volume: 1773 start-page: 1213 issue: 8 year: 2007 ident: 1025_CR12 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbamcr.2006.10.005 – volume: 372 start-page: 30 issue: 1 year: 2015 ident: 1025_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMoa1412690 – volume: 5 start-page: e14124 issue: 11 year: 2010 ident: 1025_CR67 publication-title: PLoS ONE doi: 10.1371/journal.pone.0014124 – volume: 109 start-page: 3183 issue: 10 year: 2018 ident: 1025_CR78 publication-title: Cancer Sci doi: 10.1111/cas.13763 – volume: 72 start-page: 210 issue: 1 year: 2012 ident: 1025_CR26 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-1515 – volume: 389 start-page: 255 issue: 10066 year: 2017 ident: 1025_CR52 publication-title: Lancet doi: 10.1016/S0140-6736(16)32517-X – volume: 27 start-page: 806 issue: 3 year: 2019 ident: 1025_CR54 publication-title: Cell Rep doi: 10.1016/j.celrep.2019.03.066 – ident: 1025_CR28 – volume: 38 start-page: 419 issue: 2 year: 2020 ident: 1025_CR76 publication-title: Invest New Drugs doi: 10.1007/s10637-019-00776-6 – volume: 69 start-page: 6839 issue: 17 year: 2009 ident: 1025_CR32 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-0679 – volume: 15 start-page: 163 issue: 2 year: 2020 ident: 1025_CR77 publication-title: Target Oncol doi: 10.1007/s11523-020-00714-0 – volume: 38 start-page: 3895 issue: 33 year: 2020 ident: 1025_CR42 publication-title: J Clin Oncol doi: 10.1200/JCO.20.00762 – volume: 43 start-page: 1929 issue: 12 year: 2015 ident: 1025_CR34 publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.067181 – volume: 5 start-page: 1630 issue: 10 year: 2010 ident: 1025_CR36 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181e8b3a3 – volume: 14 start-page: 1351 issue: 12 year: 2008 ident: 1025_CR68 publication-title: Nat Med doi: 10.1038/nm.1890 – volume: 48 start-page: 2661 issue: 12 year: 2009 ident: 1025_CR11 publication-title: Biochemistry doi: 10.1021/bi801898e – volume: 3 start-page: 416 issue: 5 year: 2012 ident: 1025_CR29 publication-title: ACS Med Chem Lett doi: 10.1021/ml300049d – volume: 68 start-page: 394 issue: 6 year: 2018 ident: 1025_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 – volume: 11 start-page: 720 issue: 8 year: 2009 ident: 1025_CR31 publication-title: Neoplasia doi: 10.1593/neo.09398 – volume: 26 start-page: 894 issue: 5 year: 2015 ident: 1025_CR38 publication-title: Ann Oncol doi: 10.1093/annonc/mdv072 – ident: 1025_CR19 – volume: 19 start-page: 1997 issue: 3 year: 2020 ident: 1025_CR15 publication-title: Exp Ther Med – volume: 25 start-page: e160 issue: 1 year: 2020 ident: 1025_CR75 publication-title: Oncologist doi: 10.1634/theoncologist.2019-0297 – volume: 33 start-page: 1000 issue: 9 year: 2015 ident: 1025_CR39 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.2007 – volume: 3 start-page: 11 issue: 1 year: 2003 ident: 1025_CR17 publication-title: Nat Rev Cancer doi: 10.1038/nrc969 – volume: 83 start-page: 584 issue: 5 year: 2008 ident: 1025_CR3 publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(11)60735-0 – volume: 27 start-page: 693 issue: 4 year: 2016 ident: 1025_CR59 publication-title: Ann Oncol doi: 10.1093/annonc/mdw008 – volume: 16 start-page: 2450 issue: 8 year: 2010 ident: 1025_CR37 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-1920 – volume: 29 start-page: 3574 issue: 26 year: 2011 ident: 1025_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2011.35.9638 – volume: 16 start-page: 1901 issue: 8 year: 1997 ident: 1025_CR13 publication-title: EMBO J doi: 10.1093/emboj/16.8.1901 – ident: 1025_CR25 doi: 10.1158/1538-7445.AM10-2515 – volume: 13 start-page: 1576 issue: 5 year: 2007 ident: 1025_CR23 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-1150 – volume: 117 start-page: 938 issue: 7 year: 2017 ident: 1025_CR50 publication-title: Br J Cancer doi: 10.1038/bjc.2017.271 – volume: 12 start-page: 556 issue: 3 year: 2017 ident: 1025_CR46 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.11.2218 – ident: 1025_CR74 doi: 10.1007/s10637-020-00975-6 – volume: 85 start-page: 673 issue: 4 year: 2020 ident: 1025_CR73 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-020-04038-8 – volume: 18 start-page: 4806 issue: 17 year: 2012 ident: 1025_CR35 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-0742 – volume: 53 start-page: 61 year: 2017 ident: 1025_CR8 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2016.12.001 – volume: 17 start-page: 989 issue: 5 year: 2011 ident: 1025_CR24 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-2200 – volume: 387 start-page: 1540 issue: 10027 year: 2016 ident: 1025_CR53 publication-title: Lancet doi: 10.1016/S0140-6736(15)01281-7 – volume: 56 start-page: 275 issue: 2 year: 2011 ident: 1025_CR69 publication-title: Adv Med Sci doi: 10.2478/v10039-011-0043-x – volume: 30 start-page: 1134 issue: 7 year: 2019 ident: 1025_CR56 publication-title: Ann Oncol doi: 10.1093/annonc/mdz113 – volume: 17 start-page: 984 issue: 7 year: 2016 ident: 1025_CR40 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30146-2 – volume: 17 start-page: 642 issue: 5 year: 2016 ident: 1025_CR72 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)00077-2 – volume: 410 start-page: 37 issue: 6824 year: 2001 ident: 1025_CR16 publication-title: Nature doi: 10.1038/35065000 – volume: 138 start-page: 323 issue: 2 year: 2015 ident: 1025_CR30 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2015.05.031 – volume: 4 start-page: 1090 issue: 6 year: 2013 ident: 1025_CR63 publication-title: Cell Rep doi: 10.1016/j.celrep.2013.08.023 – volume: 10 start-page: 53 issue: 1 year: 2016 ident: 1025_CR10 publication-title: Expert Rev Respir Med doi: 10.1586/17476348.2016.1115349 – volume: 31 start-page: 507 issue: 4 year: 2020 ident: 1025_CR60 publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.01.013 – volume: 78 start-page: 549 issue: 5 year: 2018 ident: 1025_CR9 publication-title: Drugs doi: 10.1007/s40265-018-0884-8 |
| SSID | ssj0061920 |
| Score | 2.5927644 |
| SecondaryResourceType | review_article |
| Snippet | BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in... Abstract BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1 |
| SubjectTerms | Amino acids Antimitotic agents Antineoplastic agents Apoptosis Binding sites Cancer Cancer Research Cancer therapies Cell differentiation Cell proliferation Chemotherapy Diarrhea Drug resistance Drug therapy Epidermal growth factor Extracellular signal-regulated kinase FDA approval Gene mutations Genetic aspects Health aspects Hematology Hypertension Immune checkpoint inhibitors Immunosuppressive agents Kinases Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell MAP kinase Medical prognosis Medical research Medicine Medicine & Public Health Medicine, Experimental MEK MEK inhibitors Metastasis Mutation Neutropenia Non-small cell lung cancer Non-small cell lung carcinoma Oncology Patients Protein-tyrosine kinase Proteins RAF Raf protein RAS Review Schedules Signal transduction Small cell lung carcinoma Targeted therapy Tumor cells Tyrosine Vomiting |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEB-kiHgRv12tGkHwoKG7m02yuQhVWgRt8aDQW0iyCX3wfJX3Xvv3dyb7YbeiXrxuZtnd385kZpLMbwBe-0p1ojOCO68ib7zX3MngeRm0L00MXolcKPxFHx-3Jyfm65VWX3QmrKcH7oHba10SdQhBiCTQ2TVOSCGVwYtU6NZksm2MesZkqp-DKSsoxxKZVu1tKtoQ5JQqEYea5HrmhjJb_-9z8hWndP3A5LVd0-yMDu_CnSGKZPv929-DG3F1H24dDfvkD-D90cFntlidLvyCuukwjEwZRnpsOlbOzhLDxJ9vfrjlktHqPVui2bNASrB-CN8PD759_MSHTgk86LLZ8tDEylVdKKWMxrhYKaeVSilp5yvnjUO7DJgrxTqWKknVqORiVLUva19XohOPYAcfGp8AM3UKQpvOR-0b1UrXtq6JiHwZkzKiLaAagbNhoBGnbhZLm9OJVtkebItg2wy21QW8ne752ZNo_FX6A_2PSZIIsPMFVAs7qIX9l1oU8JL-pu2rSScztvsYkUrMKiQ-5k2WIEPGDwhuqEdAGIgSaya5O5NEAwzz4VFj7DABbGxNpEcSXb0s4NU0THfSobZVPDvPMtS0CcODAh73CjZ9tBCY2FfGFKBnqjdDZT6yWpxmenBiBMS4vIB3o5L-eq0_o_70f6D-DG7XdOaHlqjkLuxs1-fxOdwMF9vFZv0im-glcnQ53A priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Journals dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9UwDI5gILQX7pfCgCAh8QARbdMkzQvSQJuQYBPipr1FSZqwSmc96Jwzfj92eoGOiwSviaM0ru3Yif2FkMeukA1vNGfWycAq5xSzwjuWe-VyHbyTPBUKv1WHh_XRkX43FIWtx2z38UoyWeqk1rV8vi7wUo9huIM4aIKp8-QCbHc1quP7D59H-4sRQT6Wx_x23GwLSkj9v9rjnzaks8mSZ25M00a0f-X_lnCVXB4cT7rbS8o1ci5018mlg-Fq_QZ5cbD3hrbdcetafICHgjNLwTmkUyY6XUbaLTu2PrGLBcUDf7oAS0E9ys3qJvm0v_fx1Ws2PK7AvMqrDfNVKGzR-FyIoLUNhbRKyhijsq6wTltQZQ_hVShDLqOQlYw2BFm6vHRlwRt-i2zBpOEOobqMnivduKBcJWth69pWATyTPESpeZ2RYuS38QPyOD6AsTApAqml6RljgDEmMcaojDydxnztcTf-Sv0Sf-NEiZjZqWG5-mIGFTS1jbz03nMeOXxcZbngQmpoxJLJSmbkIQqB6QtQJ803u-DECghEBEzzJFGg7sMCvB1KGIANiKI1o9yZUYLO-nn3KGhmsBlrUyJOkgDvQGTk0dSNIzEPrgvL00SD7zyBR5GR271cTovmvAKHTeuMqJnEzrgy7-na44QojiCC4Mpn5Nkotz8-689cv_tv5PfIdokJQXh-JXbI1mZ1Gu6Ti_7bpl2vHiQd_g53QT84 priority: 102 providerName: Springer Nature |
| Title | MEK inhibitors for the treatment of non-small cell lung cancer |
| URI | https://link.springer.com/article/10.1186/s13045-020-01025-7 https://www.ncbi.nlm.nih.gov/pubmed/33402199 https://www.proquest.com/docview/2478759905 https://www.proquest.com/docview/2475530471 https://pubmed.ncbi.nlm.nih.gov/PMC7786519 https://doaj.org/article/8af32ccc33f34314a353569f32956846 |
| Volume | 14 |
| WOSCitedRecordID | wos000607951800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: RBZ dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: M~E dateStart: 20080101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: RSV dateStart: 20081201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYhxAvfH8ERjESEg9gLYljO34BbagTCFpV40PlybIdh1Uq6Wg7_n58rpORIfbCS6TEFyW2z-c7393vEHpuMl7RSlKiDXekMEYQzawhqRUmlc4aTkOi8EcxmZSzmZzGA7d1DKtsZWIQ1NXSwhn5fg4oMszLTvbm9CeBqlHgXY0lNHbQLiCVFQO0eziaTI9bWQzWQdqmypR8f52BY5CAyQRYaoyI3nYUUPv_ls1_bE4XAycveE_DpnR083-7cwvdiOooPtjyz210xTV30LVxdLjfRa_How943pzMzRzK8mCv4mKvMuIuPh0va9wsG7L-oRcLDG4AvPDyA1vgptU99OVo9PntOxJLLhAr0mJDbOEynVU2ZcxJqV3GteC8rmuhTaaN1H6BW290udylvGa84LV2jucmzU2e0YreRwP_UfcQYZnXlgpZGSdMwUumy1IXzusrqau5pGWCsnbklY145FAWY6GCXVJytZ0t5WdLhdlSIkEvu3dOt2gcl1IfwoR2lICkHR4sV99VXJiq1DXNrbWU1tT_XKEpo4xL_xASKQueoKfADmqbltrJA3XgVVvmzRPmP_MiUIBE8B2wOiY2-GEAbK0e5V6P0q9k229ueUVFSbJW54ySoGddM7wJ0XGNW54FGqj-5PWMBD3YcmjXaUoLr8ZJmSDR493eqPRbmvlJwBkHaEGv4CfoVcvl57_171F_dHkvHqPrOYQFwSkW20ODzerMPUFX7a_NfL0aoh0xE-FaDuNaHoZjEn83fT-efvN3x5--_ga3HFBa |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLQIuvB-BQoME4gBRkzh24gOgAq262od6KFI5Gdtx6EpLtuxuQfwpfiMzeWxJEb31wNWeJH7MfJ6J5wHwzEQiZ7lkgTbCBYkxaaC5NUFoUxNKZ41gVaDwMB2Ps8NDub8Gv9pYGHKrbDGxAup8Zukf-VZMWWQ4Yid_e_wtoKpRdLvaltCo2WLgfv5Ak23xuv8B9_d5HO_uHLzfC5qqAoFNw2QZ2MRFOsptyLmTUrtI6FSIoihSbSJtpEYetmhXuNiFouAiEYV2TsQmjE0csZzhey_BeoLMnvVgfb8_2v_UYj9ZI2EbmpOJrUVEF5EBmWiUu40Haef4q6oE_H0W_HEYnnXUPHNbWx2Cuzf-t-W7CdcbddvfruXjFqy58jZcGTUOBXfgzWhn4E_Ko4mZUNkhH1V4H1Vif-V_788Kv5yVweKrnk59uubwp4iPviVpmd-Fjxcy-nvQw4-6B-DLuLAslblxqUlExnWW6cShPha6QkiWeRC1O61sk2-dyn5MVWV3ZULV3KGQO1TFHSr14OXqmeM628i51O-IgVaUlCm8apjNv6gGeFSmCxZbaxkrGA4u0YwzLiQ2UqBoIjzYJPZTddjtCu_UNqruHM0vjp95UVEQ4uEErG4CN3AZKHdYh3KjQ4lIZbvdLW-qBikX6pQxPXi66qYnyfuvdLOTioaqW6Ee5cH9WiJWk2YsQTVVSg_Sjqx0VqXbU06OqjzqlDoRDRgPXrVSdTqsf6_6w_NnsQlX9w5GQzXsjweP4FpMLlD0x45vQG85P3GP4bL9vpws5k8a7PDh80XL22_lM6mt |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9QwDLdgoIkXvgeFwYKExANUa5smaV6QBuwE2naaxIf2FiVpwk46etPdjb-fOP1gHR8S4rVx1MZnO_bZ_hngucl5TWtJU224S0tjRKqZNWlmhcmks4bT2Ch8KKbT6uREHl_o4o_V7n1Ksu1pQJSmZr17VvtWxSu-u8oxwZdi6IOYaCwVV-FaiUODMF7_-KW3xRgdZH2rzG_3ja6jiNr_q22-cDldLpy8lD2Nl9Lk1v8f5zbc7BxSstdK0B244pq7sHnUpdzvweuj_QMya05nZoaDeUhwcklwGslQoU4WnjSLJl190_M5wUQAmQcLQizK0_I-fJ7sf3r7Pu2GLqRWZOU6taXLdV7bjDEnpXY514Jz773QJtdG6qDiNoRdrnAZ94yX3GvneGGywhQ5rekWbISXuodAZOEtFbI2TpiSV0xXlS5d8Fgy57mkVQJ5z3tlO0RyHIwxVzEyqbhqGaMCY1RkjBIJvBz2nLV4HH-lfoM_6UCJWNrxwWL5VXWqqSrtaWGtpdTT8HGlpowyLsNDbKUseQI7KBCqbUwdLILaC84tCwEKC695ESnQJoQDWN21NgQ2ILrWiHJ7RBl02Y6Xe6FTnS1ZqQLxk1jwGlgCz4Zl3In1cY1bnEcanP8UPI0EHrQyOhya0jI4clImIEbSO-LKeKWZnUakcQQXDC5-Aq96Gf75WX_m-qN_I9-BzeN3E3X4YXrwGG4UWDOEf3GxbdhYL8_dE7huv69nq-XTqNo_AD2wSwA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MEK+inhibitors+for+the+treatment+of+non-small+cell+lung+cancer&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Han%2C+Jing&rft.au=Yang%2C+Sen&rft.au=Wu%2C+Xuan&rft.au=Li%2C+Hongle&rft.date=2021-01-05&rft.pub=BioMed+Central+Ltd&rft.issn=1756-8722&rft.eissn=1756-8722&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1186%2Fs13045-020-01025-7&rft.externalDBID=n%2Fa&rft.externalDocID=A650588257 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon |